Loading...
•
Feb 28, 2021
Nurix Q1 2021 Earnings Report
Reported financial results for the first quarter ended February 28, 2021 and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $5.0 million for the first quarter of 2021, compared to $2.9 million for the same period in 2020. The net loss was $24.3 million, or ($0.63) per share. The company's cash, cash equivalents, and investments totaled $380.3 million as of February 28, 2021, and $530.4 million proforma including net proceeds from follow-on offering.
Initiated first clinical trial to evaluate NX-2127, an orally available degrader of Bruton’s tyrosine kinase.
On track to initiate Phase 1 trials for three more proprietary drug candidates in 2021.
Expanded Sanofi collaboration resulting in option exercise payment of $22 million.
Completed a public follow-on offering with net proceeds of approximately $150 million.
Revenue by Segment
Forward Guidance
Nurix anticipates initiating Phase 1 trials for NX-1607, NX-5948 and DeTIL-0255 in the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...